# US 8,465,788 B2 · Arabinoxylans for modulating the barrier function of the intestinal surface

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,465,788 B2
- Document ID: US8465788B2
- Status: Granted
- Kind: B2
- Application number: 13/059,293
- Filed: 2009-08-18
- Published: 2012-09-13
- Granted: 2013-06-18
- Earliest claimed: 2008-08-18
- Assignees: BioActor BV
- Applicants: Peter Frank Ekhart; Hans Van Der Saag; Sam Possemiers; Pieter Van Den Abbeele; Tom Van De Wiele; Audrey Martine Neyrinck; Nathalie Maria Nelly Delzenne; Patrice D Cani
- Inventors: Peter Frank Ekhart; Hans Van Der Saag; Sam Possemiers; Pieter Van Den Abbeele; Tom Van De Wiele; Audrey Martine Neyrinck; Nathalie Maria Nelly Delzenne; Patrice D Cani
- Web page: https://patentgrep.com/patent/US8465788B2

## CPC

- A61K 31/7034: attached to a carbocyclic compound, e.g. phloridzin
- A21D 2/181: {Sugars or sugar alcohols (honey A21D2/34)}
- A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics
- A23L 33/22: Comminuted fibrous parts of plants, e.g. bagasse or pulp
- A23L 33/40: {Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula}
- A61K 8/73: Polysaccharides
- A61K 31/715: Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/12: Antidiarrhoeals
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 37/00: Drugs for immunological or allergic disorders
- A61Q 19/00: Preparations for care of the skin
- C08B 37/0057: {beta-D-Xylans, i.e. xylosaccharide, e.g. arabinoxylan, arabinofuronan, pentosans; (beta-1,3)(beta-1,4)-D-Xylans, e.g. rhodymenans; Hemicellulose; Derivatives thereof}
- C08L 5/00: Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A21D: TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS (preservation of flour or dough before baking A23B40/00; preservation of bakery products A23B45/00)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention is directed to a particular arabinoxylan (“AX”) preparation and the finding that this preparation has a beneficial effect on the organization of the intestinal microbial community in the lumen and in particular at the site of the gut mucosa, where it modulates the barrier function of the intestinal surface, primarily by modulating the mucosa-associated microbial community towards a relative increase of health beneficial bacteria, such as bifidobacteria and lactobacilli. It is accordingly a first aspect of the present invention to provide said arabinoxylan preparation characterized in comprising isolated water-soluble arabinoxylans and the use thereof to improve functioning (e.g. barrier function) of the intestinal epithelium. Thus, in a further aspect the present invention provides compositions, both pharmaceutical and nutritional compositions, comprising said arabinoxylan preparations; in particular pharmaceuticals, medical foods, food supplements or food compositions, such as infant formula products, dairy products, bakery products or pastry products. The compositions optionally comprise probiotics such as Bifidobacterium or Lactobacillus.

## Claims

### Claim 1

A method of modulating a function of an intestinal surface with a preparation containing a water-extractable arabinoxylan (AX) fraction produced from wheat comprising isolated water-soluble arabinoxylans with an average degree of polymerization of at least 60 to modulate barrier function of the human intestinal surface, the hormonal functioning of the intestinal surface, functioning of the local and/or systemic immune system, metabolic homeostasis, or a combination thereof comprising: feeding a human said preparation.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said preparation modulates the barrier function of the intestinal surface including:
stimulating growth and/or activity of one or a limited number of beneficial bacteria in the intestinal tract;
inhibiting growth and/or activity of one or a number of pathogenic bacteria in the intestinal tract;
relatively increasing the attachment of non-pathogenic bacteria to the mucosa of the gastrointestinal surface;
reducing uncontrolled uptake from the gut of antigens, pro-inflammatory molecules, bacteria or bacterial products;
providing anti-inflammatory activity at the intestinal surface;
producing specific bacterial metabolites, or a combination thereof.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the preparation causes a relative increase of beneficial bacteria at the intestinal surface.

### Claim 4 (depends on 2)

The method according to claim 2, wherein the preparation causes a relative decrease of pathogenic bacteria at the intestinal surface and/or a reduction in translocation of pathogenic bacteria from the gastrointestinal tract.

### Claim 5 (depends on 2)

The method according to claim 2, wherein the preparation causes a reduction in translocation antigens, pro-inflammatory molecules, bacteria or bacterial products from the gut.

### Claim 6 (depends on 2)

The method according to claim 2, wherein the preparation causes anti-inflammatory activity at the intestinal surface.

### Claim 7 (depends on 2)

The method according to claim 2, wherein the preparation leads to improved functioning of the local and/or systemic immune system.

### Claim 8 (depends on 2)

The method according to claim 2, wherein the preparation leads to improved metabolic homeostasis, induction of satiety, improved weight management, or a combination thereof.

### Claim 9 (depends on 1)

The method according to claim 1 wherein said water extractable arabinoxylan (AX) fraction produced from wheat comprises isolated water-soluble arabinoxylans with an average molecular weight fraction of at least 8 kDa; a degree of substitution of between 0.4 and 0.9; a protein content of up to about 22 wt %; and a total sugar concentration of at least 55 wt %.